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Abstract
Background: The advantages and utility of microRNAs (miRNAs) as diagnostic and prognostic cancer markers is at
the vanguard in recent years. In this study, we attempted to identify and validate the differential expression of
miRNAs in oral squamous cell carcinoma (OSCC), to correlate their expression with the clinico-pathological profile
of tumours and to identify the signaling pathways through which the aberrantly expressed miRNAs effect
tumourigenesis.
Methods: miRCURY LNA™ array with probes specific to 1168 miRNAs and TaqMan assays specific for 10 miRNAs
was employed to evaluate and validate miRNA expression in a discovery cohort (n = 29) and validation cohort
(n = 61) of primary OSCC tissue specimens, respectively. A computational pipeline with sequential integration of
data from miRTarBase, CytoScape, UniProtKB and DIANA-miRPath was utilized to map the target genes of
deregulated miRNAs and associated molecular pathways.
Results: Microarray profiling identified 46 miRNAs that were differentially expressed in OSCC. Unsupervised
clustering demonstrated a high degree of molecular heterogeneity across the tumour samples as the clusters did
not represent any of their clinico-pathological characteristics. The differential expression of 10 miRNAs were
validated by RT-qPCR (let-7a, let-7d, let-7f and miR-16 were downregulated while miR-29b, miR-142-3p, miR-144,
miR-203, and miR-223 were upregulated in OSCC; the expression of miR-1275 was variable in tumours, with high
levels associated to regional lymph node invasion; additionally, miR-223 exhibited an association with advanced
tumour stage/size). In silico analyses of the experimentally confirmed target genes of miRNAs revamp the
relationship of upregulated miRNAs with tumour suppressor genes and of downregulated miRNAs with oncogenes.
Further, the differentially expressed miRNAs may play a role by simultaneously activating genes of PI3K/Akt
signaling on one hand and by repressing genes of p53 signaling pathway on the other.
Conclusions: The identified differentially expressed miRNAs and signaling pathways deregulated in OSCC have
implications for the development of novel therapeutic strategies. To the best of our knowledge, this is the first
report to show the association of miR-1275 with nodal invasion and the upregulation of miR-144 in OSCC.
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Background
Oral cancer broadly encompasses tumours arising in the
lips, hard palate, upper and lower alveolar ridges, anter-
ior two-thirds of the tongue, sublingual region, buccal
mucosa, retromolar trigone and floor of the mouth [1].
Squamous cell carcinoma is the predominant (~95 %)
histological type [2] and hence the term ‘oral cancer’
tends to be used interchangeably with oral squamous
cell carcinoma (OSCC). In 2012, OSCC accounted for
145,000 deaths worldwide, with less developed regions
sharing 77 % of the burden; In India, OSCC is the lead-
ing cancer in men and fifth common cancer in women
[3]. The widespread practise of smoking or chewing to-
bacco and alcohol drinking, apart from poor oral hy-
giene, poor diet and Human Papilloma Virus (HPV)
infections may explain this disproportionately higher in-
cidence of OSCC in India [4, 5]. Although the oral cavity
is readily accessible for clinical examination, most tu-
mours are not diagnosed until they have advanced or
metastasized [6], thereby limiting the effectiveness of
chemotherapy, radiotherapy and surgery. Moreover, the
development of second primary tumours hamper the
success of multimodal therapeutic procedures leading to
poor prognosis and dismal 5-year survival rates [3, 7].
Hence, research directed towards the identification of
biomarkers for early diagnosis of OSCC, indicators of
good or bad prognosis, and determinants of treatment
response/overall survival is undeniably essential [8].
MicroRNAs (miRNAs) are short (19-to-25 nt) single
stranded non-coding RNAs, that bind to complementary
sequences present usually in the 3’ untranslated region
(UTR) of target messenger RNAs and inhibit their trans-
lation by the subsequent recruitment of RNA induced
silencing complex – RISC [9, 10]. Since > 30 % of the
human genes are predicted to be regulated by miRNAs,
these tiny RNAs govern all cellular, physiological and de-
velopmental processes [11]. MicroRNAs are encoded
throughout the genome with a vast majority located in
intergenic regions (anywhere between 57 and 69 %),
followed by intronic regions (~12 to 17 %), exonic
(~5 %), long-noncoding (5 %) and repeat regions (~8 %)
[12]. Nevertheless, around 50 % of these genomic re-
gions are frequently prone to alterations in various can-
cers and are collectively termed as cancer-associated
genomic regions (CAGRs) [13, 14]. As a consequence,
miRNA deregulation is common in all human cancers
including OSCC and miR signatures have been helpful
at all levels right from diagnosis to determination of
treatment response [15]. Majority of the miRNA expres-
sion profiling studies performed in OSCC until now rep-
resent either oral cancer cell line models [16, 17] or
tissue samples of head and neck carcinoma on the whole
[18–23]. Although oral, pharyngeal and laryngeal tu-
mours are grouped together as head and neck squamous
cell carcinoma (HNSCC), the process of carcinogenesis
is quite different leading to molecular heterogeneity [24].
Moreover, variations in risk factors and associated clinical
parameters across different geographical areas of the
world adds more complexity to OSCC [25]. Hence, study-
ing OSCC separately with sufficient number of primary
tumours is crucial to arrive at unifying conclusions. In the
present study, we profiled the expression of 1,168 mature
miRNAs in 29 OSCC primary tumours by miRCURY
LNA™ array and validated the expression of 10 candidates
by TaqMan single miRNA assays in a cohort of 61 OSCC
samples compared to 9 independent normal oral tissues.
We also tested the association of mature miRNA levels
with tumour characteristics and elucidated the underlying




The study was approved by the Institutional Review Board
of Government Arignar Anna Memorial Cancer Research
Institute and Hospital – GAAMCRIH, Kanchipuram, (Ref.
No.262/E1/2008) and Government Royapettah Hospital –
GRH, Chennai, (Ref. No. 371/RMO/2010). Informed
consent was obtained from all subjects and samples were
collected according to the ethical framework and guide-
lines of Dr. ALM PG Institute of Basic Medical Sciences,
University of Madras, Chennai. The OSCC primary tissues
were collected by punch biopsy from patients of GAAM-
CRIH. The clinico-pathological characteristics like age,
sex, the tumour TNM stage, tobacco chewing/smoking
status, alcohol consumption, etc. were documented in a
standard questionnaire. As a control, normal tissues were
obtained from the contra-lateral tumour-free side of
OSCC patients attending GRH. All specimens were trans-
ferred to sample collection tubes containing 3 mL of
RNAlater solution (Ambion, USA), and transported to the
laboratory on ice.
RNA Extraction and quality control
The equipment used for tissue processing and RNA ex-
traction were subjected to overnight DEPC treatment
(0.05 %) and autoclaved. The tissues were removed from
RNAlater upon reaching the laboratory, cut into small
pieces, transferred back to the respective tube to facili-
tate the percolation of RNAlater and stored at 4 °C for a
day. Subsequently, RNAlater was removed carefully
using pipette without any carryover and the tissues were
stored at −80 °C. At the time of homogenization, the
samples were thawed on ice, transferred to nuclease-free
2 mL microfuge tubes and weighed on an electronic bal-
ance (Sartorius, Germany). QIAzol® (Qiagen, USA) was
added to the tubes (700 μL per 50–100 mg of tissue)
followed by the addition of Zirconia beads of 1 mm
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diameter (SV Scientific, Bangalore). Homogenization
was carried out on Micro Smash MS-100 automated
homogenizer (TOMY, Japan) at 3000 rpm for 30 s. The
tubes were then allowed to cool on ice for a minute and
again homogenized at 3000 rpm for 30 s. This process
was repeated three to four times until no tissue blocks
were obvious. Finally, the homogenate was incubated for
5 min at room temperature and total RNA was extracted
using miRNeasy Mini Kit (Qiagen, USA) as per the man-
ufacturer’s protocol and recommendations. RNA quality
was assessed with Agilent 2100 Bioanalyzer (Agilent
Technologies, Inc., USA) and was judged by the RNA
integrity number (RIN). Only samples with RIN ≥ 5 were
included in the array while those with RIN < 5 were
excluded (Representative bioanalyzer eletropherogram
shown in Additional file 1). RNA concentrations were
measured on a NanoDrop ND-1000 (Thermo Scientific,
Germany) spectrophotometer.
MicroRNA microarray
The microarray experiments were conducted at Exiqon
Services, Denmark. Total RNA (800 ng) from the sample
and the reference was labeled with Hy3™ and Hy5™ fluor-
escent label, respectively, using the miRCURY LNA™
microRNA Power Labeling Kit, Hy3™/Hy5™ (Exiqon,
Denmark). The Hy3™-labeled samples and Hy5™- labeled
reference RNA were mixed pair-wise and hybridized to
the miRCURY LNA™ microRNA Array (5th gen - hsa,
mmu & rno) (Exiqon, Denmark) that contained capture
probes targeting all miRNAs for human, mouse or rat
registered in the miRBase 16.0. The hybridization was
performed according to the miRCURY LNA™ microRNA
Array instruction manual using a Tecan HS 4800™
hybridization station (Tecan, Austria). After hybridization,
the microarray slides were stored in an ozone free envir-
onment (ozone level below 2.0 ppb) to prevent potential
bleaching of the fluorescent dyes, scanned using the
Agilent G2565BA Microarray Scanner System (Agilent
Technologies, Inc., USA) and analysed using the ImaGene
9.0 software (BioDiscovery, Inc., USA). The quantified
signals were background corrected [26] (Normexp with
offset value 10) and normalized using the global Lowess
(LOcally WEighted Scatterplot Smoothing) regression
algorithm.
Reverse transcriptase quantitative PCR
Reverse transcriptase quantitative PCR (RT-qPCR) was
performed using TaqMan MicroRNA Reverse transcrip-
tion kit, TaqMan miRNA assays (Additional file 2) and
TaqMan Universal Master Mix II (without UNG). Briefly,
cDNA conversion was carried out in a total volume of
15 μL containing 100 mM dNTP, Multiscribe Reverse
Transcriptase (50 U/μL), RT buffer, RNase inhibitor, RNA
sample (10 ng/15 μL) and 5X TaqMan miRNA specific RT
primers. The cDNA was diluted 15-fold, added to 384-
well custom plates, and the subsequent PCR used miRNA
specific TaqMan assays. A negative control without tem-
plate was also included in parallel. PCR was carried out on
7900HT Real Time PCR System (Applied Biosystems,
Foster City, CA, USA) in a total volume of 10 μL with the
following thermal cycling parameters: 95 °C for 10 min
once, followed by 40 cycles of denaturation at 95 °C for
25 s and annealing/extension at 60 °C for 60 s. All reac-
tions were carried out in triplicate, the acquired data was
analysed using the RQ Manager Software and the result-
ing text file was exported to Microsoft Excel. The expres-
sion of the miRNAs were normalized to the average Ct
value of RNU44 and RNU48 (ΔCt). The relative expres-
sion of miRNAs in OSCC were calculated using the me-
dian ΔCt value of the independent normal oral tissues
(calibrator reference) by the 2-ΔΔCt method [27].
Statistical analysis
For microarray data, unsupervised analysis and super-
vised clustering analysis of the samples were carried out
by the service provider (Exiqon, Denmark). Principle
component analysis (PCA) was applied to visualize high-
dimensional data generated based on the sample group-
ings. A student’s t-test was performed to identify the
miRNAs that significantly differed between the study
groups (moderately differentiated and well differentiated
histological type of tumours). Association of the clinico-
pathological characteristics with the sample clusters
were analysed using contingency tables, followed by
Fisher’s exact test or Chi-square test as and when appro-
priate. In case of RT-qPCR, data were analysed using
GraphPad Prism 6 (GraphPad software Inc., La Jolla,
CA, USA). The fold change ratios of each miRNA was
log2 transformed and tested for normality with the
D'Agostino & Pearson omnibus test. In case of Gaussian
distribution, the difference between the two groups were
analysed using Student’s t-test. Welch correction was ap-
plied post t-test, when a significant difference in variance
was observed. In case of non-Gaussian distribution, Mann
Whitney test for independent samples was applied. All
tests were two tailed, and a P < 0.05 was considered sig-
nificant. The relative expression levels are provided as
mean with 95 % confidence interval or as median with
interquartile range wherever applicable. Association of
miRNA levels to the 10 clinico-pathological variables was
tested by either Student’s t-test or Mann Whitney test as
applicable and to account for multiple hypotheses testing,
the significance level was adjusted by Bonferroni correc-
tion to P = 0.005 (0.05/10).
In silico analyses
From the RT-qPCR data, we constructed a custom miR-
NA:tumour expression matrix (custom OncoPrint) using
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the tool “OncoPrinter” available at cBioPortal (URL:
http://www.cbioportal.org/oncoprinter.jsp) [28]. The
basis and details on how we constructed the custom
OncoPrint is described elsewhere [29]. The target genes
of miRNAs were retrieved from miRTarBase [30] avail-
able at http://mirtarbase.mbc.nctu.edu.tw/, which pro-
vides the most current and comprehensive information
of experimentally validated miRNA target interactions.
The miRNA:mRNA interactions were visualized and
analysed using CytoScape® 2.8.3 available at http://
www.cytoscape.org [31]. The targets of the downregulated
miRNAs were then compared against the list of manually
curated and reviewed human ‘oncogenes’ (Keyword:
“Proto-oncogene [KW-0656]”; URL: http://www.uniprot.
org/uniprot/?query=KW-0656&sort=score), retrieved from
the UniProt Knowledgebase, a central hub for the col-
lection of functional information on proteins with ac-
curate, consistent and rich annotation [32]. In a
similar manner, the validated targets of over expressed
miRNAs were compared against the list of human
‘tumour suppressor genes’ (Keyword: “Tumor suppressor
[KW-0043]”; URL: http://www.uniprot.org/uniprot/?
query=KW-0043&sort=score) obtained from UniProtKB.
DIANA-miRPath v2.0 [33] was used to map the uni-




miRNA profiling asserts the molecular heterogeneity of
OSCC
The present study utilized miRCURY LNA™ array (Exiqon,
Denmark), that contained capture probes for profiling the
expression of 726 mature human miRNAs annotated in
miRBase v.16.0 [34], 365 miRNAs proprietary to Exiqon,
77 viral miRNAs, and 18 other small RNAs (snoRNAs,
snRNAs and rRNA). Considering the heterogeneity of
OSCC, the common reference design [35] was adopted.
Profiling was done initially in 21 samples and hence, the
common reference pool was composed of these 21 RNA
samples. Later, 8 samples were profiled along with one
sample from the earlier batch which served as a reference
for merging the array data. After image analysis, the ob-
tained data was filtered, normalized and log2-transformed
(The microarray data/expression matrix is provided as
Additional file 3). The expression of 272 probes were de-
tectable across all the 29 samples and only these miRNAs
were included for unsupervised clustering. When sorted
by standard deviation (SD), 48 miRNAs had SD > 1 sug-
gesting their differential expression across the samples
and the respective heat map is provided as Fig. 1. We then
calculated the average ‘delta Log Median Ratio’ (dLMR)
values for each of these 48 miRNAs, and classified them
as either ‘upregulated’ if the average dLMR value was
positive or ‘downregulated’ if the average dLMR value was
negative (Table 1). Since the microarray was based on
miRBase 16, we verified the MIMATA IDs of the differen-
tially expressed miRNAs except for the Exiqon-
proprietary miRNAs, in the current version of miRBase
(Release 21, June 2014). Hsa-miR-1259 and hsa-miR-1308
were found to be misclassified dead entries according to
miRbase 21, since the former overlapped an annotated
snoRNA, while the latter was a fragment of tRNA. Thus,
the final list of differentially expressed miRBase annotated
miRNAs was limited to 24 downregulated candidates and
15 upregulated ones.
In Fig. 1, the sample-clustering tree (dendrogram) on
the top indicates the existence of two different molecular
groups (Group I and Group II) of the samples based on
the differential expression of miRNAs. Therefore, we
tested whether Group I and Group II tumours were
clustered according to any of their clinico-pathological
characteristics (Additional file 4). Surprisingly, no such
significant difference was evident. Based on the dendro-
gram, we further divided Group I and Group II into sub
groups (See Fig. 1, lower panel, Level 2 classification)
and again tested their association with the clinico-
pathological characteristics (Additional file 5). Interest-
ingly, the subgroup IIA and IIB were enriched respectively
with tumours of ‘well differentiated’ and ‘moderately
differentiated’ histology. The subgroup IB comprised tu-
mours of both histological grades while IA was composed
of two tumours obtained from patients of relatively youn-
ger age (32 and 45 years). Intrigued by the histological
grade difference, this time we performed a supervised
clustering analysis by predefining the tumours either as
‘G1 – well differentiated’ or ‘G2 – moderately differen-
tiated’. A two-tailed T-test followed by Bonferroni
correction [36] implicated that hsa-miR-223, hsa-let-7f
and hsa-let-7d could discriminate the G1 and G2
grades of OSCC (Table 2; volcano plot provided as
Additional file 6). However, principal component ana-
lysis (PCA) showed that the data points were scat-
tered in all quadrants of the plot (Fig. 2) suggesting
that neither histopathology nor any other biological
component is pronounced in a particular direction.
Taken together, our microarray results reiterate the
molecular heterogeneity of OSCC.
RT-qPCR validation of selected differentially expressed
miRNAs
To validate the microarray results by reverse transcrip-
tion quantitative PCR (RT-qPCR) and to identify an
appropriate endogenous reference, we primarily assayed
the expression of SNORD44 (RNU44), SNORD48
(RNU48), U6snRNA and miR-26b in 10 cancer and 2
control samples. The Ct value obtained from the
amplification plots (Additional file 7) demonstrated a
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high consistency in the performance of RNU44 and
RNU48, which were subsequently used for normalization.
As we have previously confirmed the aberrant expression
of two microarray prioritized candidates — miR-21 and
miR-143 — in OSCC, as a part of different studies [29, 37],
we now evaluated the expression of 10 miRNAs namely
hsa-let-7a, hsa-let-7d, hsa-let-7f, hsa-miR-16, hsa-miR-29b,
hsa-miR-142-3p, hsa-miR-144, hsa-miR-203, hsa-miR-223
and hsa-miR-1275 using TaqMan® assays in a cohort of 61
OSCC tumours (including the 29 microarray-profiled sam-
ples) compared to 9 independent normal oral specimens.
A significant upregulation of miR-29b, miR-142-3p,
miR-144, miR-203 and miR-223, and a significant
downregulation of let-7a, let-7d, let-7f and miR-16, was
observed in OSCC compared to controls (Table 3). On
the other hand, the levels of miR-1275 were slightly
high in tumours with borderline significance.
For comparison, the log transformed average expres-
sion value of each miRNA in tumours as determined by
RT-qPCR was plotted against their respective average
dLMR values obtained from microarray (Fig. 3). Con-
cordance in up-regulation or down-regulation status
amongst the datasets was observed for 7 of the 9 signifi-
cant miRNAs; opposing expression patterns between
microarray and RT-qPCR were seen in case of miR-203
and miR-223. For understanding the extent of alteration
Fig. 1 Unsupervised analysis heat map of 29 OSCC primary tumour samples. The clustering is performed on all samples, and on the top 48
microRNAs with highest standard deviation (SD > 1). Each row represents one microRNA and each column represents one sample. The microRNA
clustering tree is shown on the left and the sample clustering dendrogram is present on the top. The colour scale shown at the top illustrates
the relative expression of a miRNA across all samples: red colour represents an expression level above mean, green colour represents expression
level lower than mean. The coloured bars below the heat map represents the grouping of samples based on the branching pattern of the
dendrogram. Level I shows the natural clustering of Group I and Group II. Level 2 shows the further sub-grouping of Group I into IA & IB and that
of Group II into IIA and IIB
Table 1 The top 48 miRNAs identified to be differentially expressed in OSCC by unsupervised clustering analysis of the microarray
data
MicroRNA category Annotated in miRBase v.16 & in v.21 (n = 41) Proprietary to Exiqon (n = 7)
Down regulation (n = 30)
(excluding invalid entries, n = 28)
miR-199a/b-3p, miR-15b, miR-16, let-7a, let-7d, miR-126, miR-203, miR-199a-5p, let-7f,
miR-17, miR-106a, miR-27a, miR-130a, miR-24, miR-223, miR-143, miR-342-3p, miR-451,





Up regulation (n = 18) miR-21, miR-30e, miR-31, miR-31*, miR-193a-3p, miR-552, miR-19a, miR-19b, miR-141,




Italicized and underlined are the misclassified dead entries in miRBase 21
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of each candidate miRNA across tumours, we con-
structed an expression matrix using the RT-qPCR data
(Fig. 4). Evidently, let-7a, let-7d and let-7f was downreg-
ulated across 95, 84 and 89 % of tumours respectively,
with a strong tendency for co-occurrence. Downregula-
tion of miR-16 was observed in up to 60 % of the OSCC
samples. MiR-142-3p was found to be the top up-
regulated miRNA (overexpressed in 87 % percentage of
tumours) followed by miR-144 (61 %), miR-223 (51 %),
miR-203 (44 %) and miR-29b (25 %). Of note, the level
of miR-1275 was aberrant in 56 % of the tumours
with downregulation or upregulation seen in equal
proportions.
Association of miRNA expression levels with tumour
characteristics
Microarray profiling demonstrated the remarkable het-
erogeneity in OSCC precluding the identification of a
miR signature specifying clinical characteristics. How-
ever, individual miRNAs may be influenced by the tumor
parameters and association testing in a larger sample
size as like our validation cohort may prove fruitful (a
summary of the clinical characteristics of the 61 OSCC
specimens are presented in Additional file 8). Hence, the
tumours were stratified according to their anatomical
localization, tumour size, lymph node involvement etc.
and tested for any association with the miRNA expres-
sion levels (Table 4). The relative expression of let-7d
was significantly high in males compared to females,
while that of let-7a and let-7f was higher in tongue car-
cinoma compared to gingivo-buccal tumours. Signifi-
cantly elevated levels of miR-223 and miR-1275 was
seen in the advanced tumour group (III-IV and T3-T4)
Vs the less severe group (I-II and T1-T2). A similar high
expression of miR-223 was found additionally in G1
grade tumours compared to the G2 grade. It should be
noted that miR-223 was the top candidate identified by
supervised clustering of the microarray samples accord-
ing to their histopathology. However the other two miR-
NAs, let-7d and let-7f, did not show such an association.
Further, high level of miR-29b was seen in the T3-T4
group relative to T1-T2 tumour category. Upon classify-
ing the tumours based on their regional lymph node in-
volvement, 6 miRNAs exhibited differential expression:
miR-29b, miR-142-3p, miR-144, miR-223 and miR-1275
were elevated significantly in nodal invasion positive (N+)
tumours compared to nodal invasion negative (N−)
subgroup, while miR-203 exhibited an opposite trend.
Table 2 MicroRNAs differentially expressed between OSCC samples of moderately differentiated and well-differentiated histology
Annotation Moderate Well Difference Fold
change
p-value
Average St.dev Average St.dev
hsa-miR-223 −2.08 1.24 −0.48 1.54 1.59 3.02 <0.006
hsa-let-7f −2.27 1.31 −0.84 1.54 1.43 2.69 <0.014
hsa-let-7d −2.54 1.23 −1.35 1.60 1.19 2.28 <0.038
Supervised clustering analysis by predefining the samples into two groups based on their histology, followed by implementation of cut-offs for both significance
(P < 0.05) and fold change (>2) resulted in the identification of the 3 miRNAs shown in the table above
Fig. 2 The Principal Component Analysis (PCA) plot of oral cancer samples. The normalized log ratio values have been used for the analysis. OSCC
samples of moderately differentiated histology are labeled in green (n = 16), and those of well-differentiated histology are labeled in blue (n = 13)
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Another interesting observation was the lower levels of
miR-142-3p in smokers relative to non-smokers. When
the significance threshold was corrected for multiple
hypotheses testing (P < 0.005), only the association of high
levels of miR-223 with advanced tumour stage/size and
that of miR-1275 with N+ tumours remained significant.
Integrating miRNAs to tumourigenesis and functional
pathways
Because miRNAs function through post-transcriptional
gene repression, from miRTarBase [30] we retrieved
(August, 2015) the experimentally validated target genes
of hsa-let-7a, hsa-let-7d, hsa-let-7f, hsa-miR-16, hsa-
miR-29b, hsa-miR-142-3p, hsa-miR-144, hsa-miR-203,
and hsa-miR-223 that showed significant differential ex-
pression in the present study together with miR-21 and
miR-143 that were previously validated to be deregulated
in OSCC by us [29, 37]. Altogether, these 11 miRNAs
cumulatively targeted 2121 genes, of which 366 were tar-
geted by multiple miRNAs (ranging from 2 to 6) thus
raising the total number of miRNA:mRNA interactions
to 2388 (Additional file 9). To gain a specific insight in
cancer context, we parsed the target genes of upregu-
lated or downregulated miRNAs and compared them
against the list of manually curated ‘tumour suppressor
genes’ or ‘oncogenes’ respectively (see Methods section
for details). This analysis corroborated the inverse rela-
tionship of oncomiRs with tumour suppressor genes and
of tumour suppressor miRs with oncogenes (Fig. 5). As
anticipated, miR-21 targeted the largest number of
tumour suppressors (n = 14), among which PTEN was
additionally targeted by miR-29b and miR-144, while
Table 3 The relative expression levels of 10 RT-qPCR validated miRNAs in OSCC samples compared to control adjacent normal
tissues
microRNA Expression level in control samples Expression level in OSCC samples P-Value
hsa-let-7a 1.00 (0.94–1.45) a 0.46 (0.37–0.58) a <0.0001
hsa-let-7d 1.00 (0.73–1.42) a 0.44 (0.36–0.58) a <0.0001
hsa-let-7f 1.00 (0.86–1.26) a 0.49 (0.41–0.65) a <0.0001
hsa-miR-16 1.00 (0.93–1.09) a 0.66 (0.44–0.92) a 0.008
hsa-miR-29b 1.00 (0.87–1.08) a 1.58 (1.02–1.97) a 0.026
hsa-miR-142-3p 1.00 (0.56–1.67) a 5.94 (3.26–10.20) a <0.0001
hsa-miR-144 1.67 (0.67–2.67) b 14.26 (3.19–25.34) b 0.03
hsa-miR-203 1.00 (0.64–1.58) a 1.82 (0.99–3.57) a 0.03
hsa-miR-223 0.97 (0.56–1.38) b 2.67 (2.08–3.26) b <0.0001
hsa-miR-1275 1.05 (0.84–1.25) b 1.33 (1.09–1.57) b 0.06
aMedian (Interquartile range), since the corresponding expression levels did not follow Gaussian distribution
bMean (95 % confidence limits), since the corresponding expression levels followed Gaussian distribution
Bold faceted are the significant P-values (<0.05)
Fig. 3 A comparison of the log fold change ratios obtained from microarray and RT-qPCR for the 10 candidate miRNAs. The log2 transformed
expression value in OSCC obtained from RT-qPCR for each of the 10 miRNA is compared against its respective delta LogMedianRatio (dLMR)
derived from the microarray experiment. For clarity, we separated the 61 OSCC samples into 29 samples that were profiled by microarray and the
remaining 32 samples as an additional group. The error bars represent 95 % confidence intervals (CI)
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RHOB was also repressed by miR-223. On the other
hand, miR-16 was the most versatile miRNA targeting
21 oncogenes in total. Some of the notable oncogenes
that had multiple miRNA interactions were BCL2 (let-
7a, miR-16, and miR-143), HMGA2 (let-7a, let-7d, and
let-7f ), CCND1 (let-7f, miR-16), MYC (let-7a, let-7f ),
HRAS and KRAS (let-7a, miR-143), and KMT2A (let-d,
miR-16).
Further, we separately examined the targets of down-
regulated and upregulated miRNAs, for enriched func-
tional pathways using DIANA-miRPath v.2 [33]. The
miRNA vs pathway heatmaps provided in Fig. 6 show
that ‘pathways in cancer’, ‘prostate cancer’, ‘non-small cell
lung cancer’, ‘glioma’, ‘pancreatic cancer’, ‘chronic myeloid
leukaemia’ etc., were significantly enriched in case of
both downregulated and upregulated miRNAs. As this
observation is accountable to the functional redundancy
of genes across multiple cancer types, we focused our at-
tention on to specific signaling mechanisms. Remark-
ably, 48 genes at different levels of the PI3K/Akt
signaling pathway were targeted by the tumour suppres-
sor miRs let-7a, let-7d, let-7f, miR-16, and/or miR-143
(Fig. 7) whereas 11 genes of the p53 signaling pathway
were targeted by the oncomiRs miR-21, miR-29b, miR-
142-3p and miR-203 (Fig. 8). Based on these results, we
propose that the aberrantly expressed miRNAs may sim-
ultaneously elicit the constitutive activation of PI3K/Akt
pathway and the suppression of the p53 pathway.
Discussion
OSCC is as a major life-threatening malignancy in India
[3, 38]. Geographical differences in incidence and mor-
tality, heterogeneity in anatomical localization, associ-
ation with a broad spectrum of risk factors, and the
unpredictable treatment outcome renders OSCC as one
of the most complex cancer. Despite multimodal ther-
apy, the 5-year survival rates of OSCC patients has not
crossed 50 % for the past 4 decades [3, 7]. Accumulating
evidences suggest that miRNAs may not only prove use-
ful as diagnostic and prognostic markers for cancer, but
also offer the competency for targeted therapies [39].
Hence, microarray and RT-qPCR has been widely ap-
plied by various researchers to identify miRNAs that are
differentially expressed in head and neck/oral cavity can-
cers [18–23, 40–42]. However, there has been a difficulty
in characterizing a consistent miRNA signature. Also,
because of the constant discovery of new mature miR-
NAs, the expression of several of them remains to be
studied. Hence, evaluating global miRNA expression and
testing their association with tumour characteristics is a
promising requisite to improve diagnosis, approaches to
therapy and to reduce the burden of OSCC in India.
In the current study, the expression of 1,168 miRNAs
were profiled in 29 OSCC primary tissues of south In-
dian ethnicity using miRCURY LNA™ array that offers
key benefits such as high specificity, high sensitivity, and
the efficient discrimination of closely related miRNA
species [43]. Moreover, the common reference design
adopted herein is considered to be advantageous as it
ideally contains all miRNAs found in any of the samples,
offers direct comparison and normalization of individual
samples to a common factor, allows the separation of
technical and biological variation, and the identification
of outlying samples among replicates [35]. Further, the
common reference is ideal for heterogeneous samples
and when the profiling is performed in batches [35].
Unsupervised hierarchical clustering of the tumours and
miRNAs suggested that the naturally arising clusters do
not represent the clinical tumour characteristics.
Principle component analysis indicated that the miRNA
Fig. 4 Expression matrix of the 10 RT-qPCR validated miRNAs across the 61 oral squamous cell carcinoma samples. The Expression matrix, otherwise
called as the ‘OncoPrint’, represents a graphical summary of alterations in the expression level of the 10 candidate miRNAs as evaluated by RT-qPCR
across 61 oral tumours. The colour coded glyphs denote changes in miRNA expression (red = overexpression; green= down regulation; white – expression
level within the range observed in the normal control samples). The name of the each miRNA and each sample is provided on the left and top of the
matrix, respectively. The values (in %) on the right side of the image and parallel to each miRNA correspond to the total percentage of tumours with
altered miRNA expression
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Table 4 Association of miRNA expression levels with clinical variables
Variable let-7a let-7d let-7f miR-16 miR-29b miR-142-3p miR-144 miR-223 miR-203 miR-1275
Age (in yrs.)
<60 0.49 ± 0.22 0.44 (0.11–1.25) 0.51 (0.2–1.25) 0.6 (0.01–1.45) 1.58 (0.02–7.79) 5.76 (0.07–39.44) 10.05 ± 14.29 2.54 ± 2.12 1.95 (0–9.25) 1.37 ± 0.99
≥60 0.49 ± 0.17 0.43 (0.26–2.98) 0.49 (0.31–2.20) 0.68 (0.22–2.48) 1.59 (0.21–5.37) 6.24 (0.29–17.81) 19.94 ± 64.44 2.86 ± 2.56 1.72 (0.13–11.01) 1.28 ± 0.84
P value 0.92 0.69 0.92 0.74 0.63 0.33 0.45 0.6 0.32 0.72
Gender
Male 0.54 ± 0.16 0.51 (0.31–2.98) 0.55 (0.22–2.2) 0.68 (0.22–2.48) 1.42 (0.02–7.79) 5.61 (0.07–13.41) 6.79 ± 7.35 2.54 ± 2.19 1.89 (0.13–9.25) 1.15 ± 0.55
Female 0.45 ± 0.21 0.42 (0.11–1.63) 0.45 (0.2–1.25) 0.55 (0.01–1.45) 1.59 (0.25–7.18) 6.51 (0.69–39.44) 19.82 ± 56.45 2.78 ± 2.41 1.73 (0–11.01) 1.47 ± 1.11
P value 0.06 0.028 0.08 0.58 0.35 0.07 0.19 0.69 0.41 0.15
Anatomical site
GBC 0.47 ± 0.20 0.42 (0.11–2.98) 0.46 (0.2–2.2) 0.65 (0.01–2.48) 1.56 (0.02–7.79) 6.33 (0.07–39.44) 16.03 ± 47.12 2.74 ± 2.16 1.72 (0–11.01) 1.34 ± 0.98
Tongue 0.60 ± 0.14 0.52 (0.35–0.76) 0.59 (0.47–0.92) 0.66 (0.42–1.32) 1.63 (0.54–2.44) 4.36 (0.48–9.37) 5.28 ± 5.06 2.31 ± 3.05 2.69 (0.36–4.3) 1.28 ± 0.61
P value 0.05 0.16 0.01 0.85 0.99 0.09 0.12 0.59 0.25 0.84
Clinical stage
I or II 0.60 ± 0.20 0.55 (0.34–0.82) 0.67 (0.43–0.78) 0.77 (0.4–1.11) 0.84 (0.58–1.61) 2.17 (0.48–9.37) 2.80 ± 2.39 1.17 ± 0.63 3.14 (1.73–6.14) 0.92 ± 0.26
III or IV 0.49 ± 0.20 0.44 (0.23–2.98) 0.51 (0.22–2.2) 0.6 (0.01–2.48) 1.61 (0.02–7.79) 5.94 (0.07–39.44) 17.11 ± 48.91 2.84 ± 2.49 1.82 (0.26–9.25) 1.40 ± 1.01
P value 0.33 0.63 0.39 0.68 0.06 0.1 0.05 0.004 0.17 0.03
Tumour Size
T1 or T2 0.56 ± 0.16 0.44 (0.34–0.82) 0.58 (0.42–0.78) 0.79 (0.4–1.13) 1.01 (0.54–1.70) 2.93 (0.48–15.76) 3.56 ± 3.52 0.95 ± 0.62 2.73 (0.53–7.9) 1.02 ± 0.28
T3 or T4 0.49 ± 0.21 0.46 (0.23–2.98) 0.49 (0.22–2.2) 0.55 (0.01–2.48) 1.67 (0.02–7.79) 5.94 (0.07–39.44) 19.02 ± 52.15 3.14 ± 2.53 1.75 (0.26–9.25) 1.44 ± 1.07
P value 0.31 0.91 0.23 0.13 0.006 0.21 0.07 ≤0.0001 0.11 0.03
Nodal invasion
N- 0.60 ± 0.18 0.55 (0.34–0.82) 0.67 (0.43–0.98) 0.64 (0.4–1.11) 0.84 (0.45–1.61) 1.84 (0.48–9.37) 2.20 ± 2.09 1.48 ± 0.85 4.24 (1.73–9.25) 0.85 ± 0.23
N+ 0.49 ± 0.20 0.44 (0.23–2–98) 0.51 (0.22–2.2) 0.6 (0.01–2.48) 1.65 (0.02–7.79) 6.15 (0.07–39.44) 17.82 ± 49.88 2.87 ± 2.54 1.75 (0.26–7.9) 1.43 ± 1.02
P value 0.22 0.63 0.31 0.78 0.009 0.007 0.04 0.01 0.01 0.003
Histological grade
G1/well 0.53 ± 0.25 0.43 (0.23–1.63) 0.46 (0.22–1.25) 0.67 (0.22–1.45) 1.59 (0.02–7.79) 7.52 (0.07–39.44) 21.97 ± 68.38 3.42 ± 2.95 2.21 (0.26–11.01) 1.43 ± 0.88
G2/moderate 0.47 ± 0.13 0.44 (0.26–0.85) 0.52 (0.34–0.98) 0.57 (0.01–1.13) 1.60 (0.45–7.18) 5.28 (0.67–15.76) 9.79 ± 14.40 1.99 ± 1.33 1.74 (0.28–9.25) 1.18 ± 0.97
P value 0.34 0.78 0.96 0.23 0.77 0.25 0.41 0.04 0.42 0.33
Smoking
Yes 0.56 ± 18 0.46 (0.32–2.98) 0.55 (0.22–2.2) 0.68 (0.22–2.48) 1.23 (0.02–4.92) 3.6 (0.07–13.41) 4.72 ± 4.76 2.62 ± 2.54 1.96 (0.27–9.25) 1.06 ± 0.59
No 0.48 ± 0.20 0.44 (0.23–1.63) 0.47 (0.27–1.25) 0.59 (0.01–1.45) 1.64 (0.25–7.79) 6.27 (0.69–39.44) 18.90 ± 52.86 2.73 ± 2.38 1.84 (0.26–7.90) 1.43 ± 1.05













Table 4 Association of miRNA expression levels with clinical variables (Continued)
Yes 0.47 ± 0.17 0.44 (0.23–2.98) 0.46 (0.27–2.2) 0.65 (0.01–2.48) 1.61 (0.25–7.18) 5.94 (0.69–17.81) 19.41 ± 54.98 2.89 ± 2.65 1.72 (0.26–7.9) 1.46 ± 1.07
No 0.55 ± 0.25 0.43 (0.26–1.25) 0.55 (0.22–1.25) 0.66 (0.22–1.45) 1.25 (0.02–7.79) 4.32 (0.07–39.44) 6.10 ± 5.51 2.31 ± 1.76 3.44 (0.36–9.25) 1.04 ± 0.62
P value 0.22 0.74 0.24 0.66 0.27 0.13 0.15 0.42 0.06 0.07
Alcohol intake
Yes 0.52 ± 0.16 0.57 (0.32–2.98) 0.53 (0.22–2.2) 0.66 (0.22–2.48) 1.65 (0.02–4.92) 5.46 (0.07–13.41) 7.15 ± 7.41 2.97 ± 2.59 1.75 (0.27–5.97) 1.17 ± 0.61
No 0.49 ± 0.21 0.42 (0.23–1.63) 0.47 (0.27–1.25) 0.65 (0.01–1.45) 1.56 (0.25–7.79) 6.38 (0.48–39.44) 18.32 ± 53.62 2.60 ± 2.35 2.09 (0.26–9.25) 1.39 ± 1.07
P value 0.55 0.06 0.38 0.92 0.94 0.3 0.21 0.62 0.54 0.34
For miRNAs that followed Gaussian distribution, the expression levels are provided as mean ± SD. For miRNAs that did not follow Gaussian distribution, the expression levels are provided as median (range). The












expression is not pronounced in any specific direction
further confirming the molecular heterogeneity of
OSCC. A similar molecular heterogeneity in Indian
OSCC unrelated to differentiation subtypes or clinical
tumour stage was reported already by a study when a
clustering analysis of samples was performed with differ-
entially expressed miRNAs [44]. This suggests the need
for more studies with large number of samples to advo-
cate a ‘miRNA expression-based classification’ system of
OSCC and to test the association of different classes
with prognosis. Out of the 46 differentially expressed
miRNAs identified by microarray, we validated the ex-
pression of 10 miRNAs by RT-qPCR in a cohort of 61
OSCC samples compared to 9 independent normal oral
tissues. While we faced some complications in obtaining
paired normal tissues, previous studies have demon-
strated that control tissues amounting to 10 % of the
total sample size is adequate [45, 46]. A general agreement
in significance and the trend of expression was observed
between microarray and RT-qPCR for let-7a, let-7d, let-7f,
miR-16, miR-29b, miR-142-3p, and miR-144. Although
both microarray and RT-qPCR confirmed the differential
expression of miR-203 and miR-223 in OSCC, a difference
in the expression pattern was observed between both
techniques. The expression of miR-1275 significantly
varied only between nodal invasion positive and nodal in-
vasion negative tumours but was near borderline signifi-
cance when all tumours were considered as a single group
and compared against the controls. Discrepancies or low
correlation in expression profiles between the array and
RT-qPCR is not new as it has been previously reported
and suggested to have arisen due to the decreased sensi-
tivity, reliability and a higher false positive rate associated
with microarray [47, 48].
Let-7 miRNAs regulate the expression of RAS [49] and
several other genes involved in the cell cycle thereby
repressing cell division both directly and indirectly [50].
Reduced expression of most members of the let-7 family
has been noted as a characteristic feature of HNSCC
[17, 51]. It is interesting to note that RAS oncogene acti-
vation by mutation and amplification was reported to be
more frequent (>25 %) in OSCC of India [52–54]. Even
the precursor molecules of let-7a and let-7d were re-
ported to be down regulated in HNSCC and addition-
ally, low levels of let-7d had an association with poorer
prognosis [20]. Recently, let-7a was found to repress
stemness-associated genes in tumour-initiating cells [55]
and let-7d was shown to negatively modulate EMT in
OSCC cell lines [56]. Similar to let-7, miR-16 is fre-
quently deleted and/or down regulated in many types of
cancer [57]. Several targets of miR-16 including BCL2,
MCL1, CCND1 and WNT3A may explain its role in
modulating the cell cycle, inhibiting cell proliferation,
promoting apoptosis and suppressing tumourigenicity
both in vitro and in vivo [57, 58]. However, miR-16 was
reported to be upregulated in OSCC cell lines [17] and
tumour tissues [21], whereas it was downregulated in tu-
mours of the OSCC animal model [59]. Notably, a study
Fig. 5 Inverse relationship of upregulated miRs with oncogenes, and downregulated miRs with tumour suppressor genes. Shown here are the
interactions between (a) the over expressed miRNAs and tumour suppressor genes, and (b) the down regulated miRNAs and oncogenes. Data
obtained by comparing the validated targets of each miRNA obtained from miRTarBase against the list of manually curated ‘Tumour suppressor
genes’ or ‘Oncogenes’ retrieved from UniProt Knowledgebase. The flags represent miRNAs, the rectangular boxes represent their target genes and
the discontinuous lines connecting them represent the interaction
Manikandan et al. Molecular Cancer  (2016) 15:28 Page 11 of 17
on Indian OSCC samples showed that a decrease in the
expression of miR-16 along with miR-125a and miR-184
is associated with oral tumourigenesis [60]. Supporting
their general tumour suppressive nature, we observed
the downregulation of let-7a, let-7b, let-7d, and miR-16
in OSCC. Moreover, the difference in the levels of let-7d
between males and females, and that of let-7a and let-7f
between tumours of the tongue and gingivo-buccal com-
plex certainly needs confirmation.
Herein, miR-29b was overexpressed in OSCC, a
phenomenon also seen in HNSCC tissues and cell lines
[17, 21]. On the contrary, enforced expression of miR-29
family inhibited tumourigenicity in lung cancer cell lines
[61], suggesting their reversed roles in different types of
cancer. miR-142-3p was first identified for its function
in the development of the lymphoid system [62], and
was subsequently implicated as an oncomiR in leukae-
mia [63]. Deregulation of miR-142-3p and miR-142-5p
along with 33 other miRNAs constituted a miR signature
specific to malignant oral neoplasms [46]. Our results
on the upregulation of miR-142-3p in OSCC agrees well
with previous HNSCC studies [19, 21]. Although miR-
144 was found to be frequently upregulated in nasopha-
ryngeal carcinoma [64], its differential expression in
OSCC has not been previously described. We noticed
a > 8 fold upregulation of miR-144 in OSCC compared
to controls. The association of miR-29b with tumour
size, that of miR-29b, miR-142-3p and miR-144 with
regional lymph node invasion, and the additional link
between miR-142-3p and smoking clearly warrants fur-
ther confirmation from upcoming studies.
miR-203 is a stemness-inhibiting miRNA that induces
epidermal differentiation by targeting ΔNp63 and
restricting proliferative potential [65, 66]. In addition,
genotoxic damage in JHU-012 (HNSCC) cell line simul-
taneously increased miR-203 expression and decreased
ΔNp63 levels thereby inducing cell death [65]. In oral
cancer, miR-203 was observed to be downregulated due
Fig. 6 Heat map of differentially expressed miRNAs versus significantly enriched functional pathways. a heat map of downregulated miRNAs Vs
functional pathways; b heat map of upregulated miRNAs Vs functional pathways. In both heat maps, darker colours represent higher statistical
significance as indicated by the colour key at the bottom. The attached dendrograms on both axes depict hierarchical clustering results for
miRNAs and pathways, respectively. Boxed by dashed lines are the functionally relevant pathway clusters that overlap the highest number of
miRNAs. Indicated by arrow mark are the pathways that were explored further. Figure developed from the output of Diana miRpath V.2
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to DNA hypermethylation [16]. In our study, the average
dLMR value obtained from microarray indicated that
miR-203 is generally downregulated in OSCC, while RT-
qPCR demonstrated its overexpression. This discordance
may be attributed to (i) the use of different calibrator for
normalization (common reference pool in microarray
and normal tissues in RT-qPCR), (ii) different sample
size, (iii) different time points at which these experi-
ments were performed, and (iv) the use of different
quantitative values for expression (dLMR for microarray
and fold change in case of RT-qPCR). However, the de-
creased levels of miR-203 in N+ tumours highlight its
anti-proliferative and anti-metastatic potential. As like
miR-203, the expression of miR-223 also showed differ-
ent trends when assessed by microarray and RT-qPCR.
Nonetheless, the level of miR-223 was significantly
higher in tumours of advanced stage/size even after
Bonferroni correction, implying its participation in
tumour growth and invasion. Enhanced expression of
the hematopoietic specific [67] miR-223 has been
consistently observed in HNSCC [21, 68]. Recent
studies demonstrate the over expression of miR-1275
in adrenocortical carcinoma patients [69]. Moreover,
high levels of miR-1275 were also found in breast
cancer cell lines and prostate cancer cell line whereas
low levels was characteristic of a glioma cell line [70].
Dysregulation of miR-1275 has not been reported
until now in OSCC/HNSCC and our results reveal
high levels of this particular miRNA in N+ tumours
as compared to N− tumors, an observation that was
significant even after Bonferroni correction. Further
research in this direction will aid in elucidating the
benefits of using some of these miRNAs as therapeutic
targets in the battle against cancer.
Despite the association of several miRNAs with
OSCC/HNSCC, little is known about the functional
pathways. Numerous studies have identified several tar-
get genes for each miRNA and hence we investigated
Fig. 7 MicroRNAs downregulated in OSCC target multiple genes in the PI3K/AKT pathway. Shown here are the 5 miRNAs significantly downregulated
in OSCC and their validated target genes that participate in the PI3K/Akt signaling pathway (hsa04151). Blue rectangles represent the miRNAs, yellow
rectangles represent genes targeted by only one miRNA, and orange rectangles represent genes targeted by more than one miRNA. Green rectangles
represent genes that are not targeted by any of the miRNAs studied herein. Figure developed from the output of Diana miRpath V.2
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the experimentally confirmed targets of the RT-qPCR
validated miRNAs for enriched functions and pathways.
Construction and visualization of a miRNA:mRNA inter-
action network suggested the involvement of 2121 genes.
Considering that the human genome contains ~ 30,000
protein coding genes, there is a possibility of up to 7.07 %
of them being deregulated by the cumulatively action of
let-7a, let-7d, let-7f, miR-16, miR-29b, miR-142-3p, miR-
144, miR-203, miR-223, miR-21 and miR-143. Comparison
of the targets of downregulated miRNAs against ‘Onco-
genes’ and that of upregulated miRNAs against ‘tumour
suppressor genes’ demonstrated the existence of an inverse
relationship. We also observed a strong link between the
downregulated miRNAs and the PI3K/Akt signalling path-
way. Accumulating genetic and cancer biology evidence
demonstrate that PI3K/AKT pathway is under the tight
regulation of miRNAs [71, 72]. The PI3K/PTEN/AKT/
mTOR signaling axis is critical for maintaining the homeo-
stasis in proliferation, metabolism, migration, apoptosis,
etc., [73] and its deregulation or constitutive activation due
to mutations has been implicated in oral carcinogenesis
[74–76]. More than 47 % of HNSCC and specifically 38 %
of Indian OSCC samples have been suggested to carry at
least one molecular alteration in this pathway [74, 77].
Thus, loss of miRNAs’ control on PI3K/AKT signaling can
have dire biological consequences. Alternatively, the
overexpression of miR-21 and miR-29b can repress
PTEN preventing it from negatively regulating the
PI3K/AKT signaling.
A similar enrichment analysis of the target genes of
upregulated miRNAs revealed that P53 signaling path-
way is commonly affected. The pivotal role of p53 in
tumour suppression is evident from the fact that more
than 50 % of HNSCCs harbour inactivating p53 muta-
tions or loss of its genomic loci [74, 78, 79]. Mutations
apart, p53 is controlled at several levels including tran-
scription, post-transcriptional regulation by miRNAs,
post-translational modification etc. Several miRNAs have
been shown to directly target and impair p53 functions,
while there are also miRNAs regulated by the tran-
scriptional activity of p53 [80]. Since p53 mutations
are relatively infrequent in the Indian OSCC population
compared to the world [81–83], we propose that miRNA
mediated repression may operate as an alternate mechan-
ism of p53 inactivation. In summary, aberrant expression
and dysfunction of miRNAs may be reckoned as a crucial
step in oral cancer initiation and progression. Some
of the presently studied miRNAs may turn out to be
important diagnostic, prognostic and predictive bio-
markers for OSCC in the future.
Fig. 8 MicroRNAs upregulated in OSCC repress multiple genes in the p53 signaling pathway. Shown here are the 4 miRNAs significantly
upregulated in OSCC and their validated target genes that participate in the p53 signaling pathway (hsa04115). Blue rectangles represent the
miRNAs, yellow rectangles represent genes targeted by only one miRNA, and orange rectangles represent genes targeted by more than one
miRNA. Green rectangles represent genes that are not targeted by any miRNA studied herein. Figure developed from the output of Diana
miRpath V.2
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Conclusion
Research striving towards early detection and efficient
management of OSCC is of utmost importance in India,
which is considered as the world capital of oral cancer.
As evidences point out the benefits and practicality of
using miRNAs as cancer biomarkers, we profiled the
expression of 1168 microRNAs (miRNAs) in primary
OSCC tumours by microarray. Unsupervised analysis
identified 46 miRNAs to be differentially expressed in
OSCC. Clustering of the samples based on the dendro-
gram and principle component analysis demonstrated
the high heterogeneity of OSCC. Validation of 10 differ-
entially expressed candidates was carried out using ma-
ture miRNA specific stem-loop primers and TaqMan
probes in a spectrum of 61 OSCC samples compared to
9 independent adjacent normal tissues. The reduced
expression of let-7a, let-7d, let-7f, miR-16, and overex-
pression of miR-29b, miR-142-3p, miR-144, miR-203,
and miR-223 were confirmed in OSCC, while miR-1275
showed borderline statistical significance. Univariate
analysis on samples stratified according to their tumor
characteristics followed by Bonferroni correction indicated
that high levels of miR-223 was associated with advanced
tumor stage and size whereas high levels of miR-1275
were associated with regional lymph node invasion. To
comprehend the signaling pathways and functional net-
works participating in OSCC pathogenesis, the validated
targets of the significantly deregulated miRNAs were re-
trieved from miRTarBase database and subjected to KEGG
pathway enrichment analyses. The downregulated miR-
NAs targeted genes enriched in the PI3K/Akt signaling
thereby activating limitless replication potential. Con-
versely, the up regulated miRNAs targeted genes enriched
in the p53 signaling pathway, the inhibition of which may
lead to evasion of apoptosis and defects in cell cycle
checkpoints. Taken together, the results suggest that alter-
ations in the cellular level of miRNAs might have a major
impact on the proteome of the cancer cell thereby con-
tributing to oral tumorigenesis.
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